UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit (www.cnbc.com)

British pharma giant GSK announced it will invest at least $30 billion in U.S. R&D and manufacturing over the next five years, including a $1.2 billion allocation specifically for advanced manufacturing, AI and advanced digital technologies to build “next‑generation biopharma factories and laboratories.” The commitment—announced during President Trump’s state visit to the U.K.—is positioned as a boost to the company’s U.S. research base and supply chain, and signals a major corporate bet on digital transformation in biopharma. For the AI/ML community this is significant because it represents large-scale, sustained capital toward embedding machine learning across the drug lifecycle: discovery, development, manufacturing and supply‑chain operations. The funding could accelerate deployment of ML-driven target discovery and phenotypic screens, digital twins and process‑control models for continuous manufacturing, predictive maintenance for facility automation, and data platforms for regulatory‑grade model validation. It also implies increased demand for annotated biomedical datasets, cloud compute, MLOps, and cross‑sector collaborations (startups, academia, regulators). While specifics on vendor partners or product plans are pending, the move materially expands opportunities for AI tools to be integrated into regulated biopharma workflows at industrial scale.